111 related articles for article (PubMed ID: 27681137)
1. Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.
Lacombe B; Morel M; Margottin-Goguet F; Ramirez BC
J Virol; 2016 Dec; 90(23):10972-10980. PubMed ID: 27681137
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone and XPB: An Old Drug with a New Molecular Target.
Gabbard RD; Hoopes RR; Kemp MG
Biomolecules; 2020 May; 10(5):. PubMed ID: 32414008
[TBL] [Abstract][Full Text] [Related]
3. Differences in Transcriptional Dynamics Between T-cells and Macrophages as Determined by a Three-State Mathematical Model.
DeMarino C; Cowen M; Pleet ML; Pinto DO; Khatkar P; Erickson J; Docken SS; Russell N; Reichmuth B; Phan T; Kuang Y; Anderson DM; Emelianenko M; Kashanchi F
Sci Rep; 2020 Feb; 10(1):2227. PubMed ID: 32042107
[TBL] [Abstract][Full Text] [Related]
4. Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways.
Olmedo DA; López-Pérez JL; Del Olmo E; Bedoya LM; Sancho R; Alcamí J; Muñoz E; Feliciano AS; Gupta MP
Molecules; 2017 Feb; 22(2):. PubMed ID: 28218730
[TBL] [Abstract][Full Text] [Related]
5. Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity.
Carpenter MA; Kemp MG
JID Innov; 2021 Sep; 1(3):100023. PubMed ID: 34909723
[TBL] [Abstract][Full Text] [Related]
6. Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1-infected cells.
Ni F; Hu K; Li M; Yang M; Xiao Y; Fu M; Zhu Z; Liu Y; Hu Q
Mol Ther; 2024 May; ():. PubMed ID: 38734901
[TBL] [Abstract][Full Text] [Related]
7. Concomitant emergence of the antisense protein gene of HIV-1 and of the pandemic.
Cassan E; Arigon-Chifolleau AM; Mesnard JM; Gross A; Gascuel O
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11537-11542. PubMed ID: 27681623
[TBL] [Abstract][Full Text] [Related]
8. Hyperactivation of mammalian target of rapamycin complex 1 by HIV-1 is necessary for virion production and latent viral reactivation.
Kumar B; Arora S; Ahmed S; Banerjea AC
FASEB J; 2017 Jan; 31(1):180-191. PubMed ID: 27702769
[TBL] [Abstract][Full Text] [Related]
9. Short Communication: Potential Risk of Replication-Competent Virus in HIV-1 Env-Pseudotyped Virus Preparations.
Bilska M; Tang H; Montefiori DC
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):368-372. PubMed ID: 27758116
[TBL] [Abstract][Full Text] [Related]
10. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
Darcis G; Bouchat S; Kula A; Van Driessche B; Delacourt N; Vanhulle C; Avettand-Fenoel V; De Wit S; Rohr O; Rouzioux C; Van Lint C
AIDS; 2017 Jan; 31(2):181-189. PubMed ID: 27755105
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of latent HIV-1 in latently infected cells by coumarin compounds: Hymecromone and ScoparoneReactivation of Latent HIV-1 in Latently Infected Cells by Coumarin Compounds: Hymecromone and Scoparone.
Li X; Zeng H; Wang P; Lin L; Liu L; Zhen P; Fu Y; Lu P; Zhu H
Curr HIV Res; 2016; 14(6):484-490. PubMed ID: 27697031
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.
Elinoff JM; Chen LY; Dougherty EJ; Awad KS; Wang S; Biancotto A; Siddiqui AH; Weir NA; Cai R; Sun J; Preston IR; Solomon MA; Danner RL
Cardiovasc Res; 2018 Jan; 114(1):65-76. PubMed ID: 29036418
[TBL] [Abstract][Full Text] [Related]
13. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
Jin H; Li D; Lin MH; Li L; Harrich D
Viruses; 2020 Apr; 12(4):. PubMed ID: 32276443
[TBL] [Abstract][Full Text] [Related]
14. Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.
Mediouni S; Chinthalapudi K; Ekka MK; Usui I; Jablonski JA; Clementz MA; Mousseau G; Nowak J; Macherla VR; Beverage JN; Esquenazi E; Baran P; de Vera IMS; Kojetin D; Loret EP; Nettles K; Maiti S; Izard T; Valente ST
mBio; 2019 Feb; 10(1):. PubMed ID: 30723126
[TBL] [Abstract][Full Text] [Related]
15. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 transcriptional modulation: novel host factors and prospective therapeutic strategies.
Gibaut QMR; Mori LP; Valente ST
Curr Opin HIV AIDS; 2023 Sep; 18(5):264-272. PubMed ID: 37535041
[TBL] [Abstract][Full Text] [Related]
17. Randomized Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Myocardial Perfusion and Function Among Persons With Human Immunodeficiency Virus (HIV)-Results From the MIRACLE HIV Study.
Srinivasa S; Walpert AR; Thomas TS; Huck DM; Jerosch-Herold M; Islam S; Lu MT; Burdo TH; deFilippi CR; Dunderdale CN; Feldpausch M; Iyengar S; Shen G; Baak S; Torriani M; Robbins GK; Lee H; Kwong R; DiCarli M; Adler GK; Grinspoon SK
Clin Infect Dis; 2023 Oct; 77(8):1166-1175. PubMed ID: 37243345
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR.
Huang T; Cai J; Wang P; Zhou J; Zhang H; Wu Z; Zhao J; Huang Z; Deng K
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0006723. PubMed ID: 37212670
[TBL] [Abstract][Full Text] [Related]
19. Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors.
Mediouni S; Lyu S; Schader SM; Valente ST
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146786
[TBL] [Abstract][Full Text] [Related]
20. Cure and Long-Term Remission Strategies.
Mori L; Valente ST
Methods Mol Biol; 2022; 2407():391-428. PubMed ID: 34985678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
